Detail akcie Precigen Rg online

Business Summary: Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Precigen Inc revenues increased 87% to $5.1M. Net loss applicable to common stockholders increased from $106.5M to $406.1M. Revenues reflect Service revenues increase of 15% to $2.8M, Product revenues increase of 73% to $406K, Other revenues increase from $22K to $57K. Higher net loss reflects General and administrative - Balancing increase of 80% to $46.2M (expense).